The stock of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) is a huge mover today! The stock decreased 5.04% or $0.74 during the last trading session, hitting $13.93. About 96,355 shares traded hands. Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) has risen 76.32% since April 27, 2016 and is uptrending. It has outperformed by 71.10% the S&P500.
The move comes after 9 months negative chart setup for the $325.18 million company. It was reported on Nov, 30 by Barchart.com. We have $13.51 PT which if reached, will make NASDAQ:AQXP worth $9.76M less.
Analysts await Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) to report earnings on March, 13. They expect $-0.60 earnings per share, down 122.22% or $0.33 from last year’s $-0.27 per share. After $-0.46 actual earnings per share reported by Aquinox Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 30.43% negative EPS growth.
Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Ratings Coverage
Out of 5 analysts covering Aquinox Pharma (NASDAQ:AQXP), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. Aquinox Pharma has been the topic of 6 analyst reports since September 11, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Tuesday, October 6 by Guggenheim. The company was maintained on Tuesday, March 15 by Jefferies. Jefferies maintained Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) on Friday, August 5 with “Hold” rating. Canaccord Genuity maintained the shares of AQXP in a report on Friday, September 11 with “Hold” rating. The firm has “Outperform” rating given on Monday, September 21 by Leerink Swann. The rating was initiated by Needham on Friday, October 23 with “Buy”.
According to Zacks Investment Research, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada.”
More recent Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) news were published by: Marketwatch.com which released: “Aquinox stock rockets 2000%, Twitter goes nuts” on August 10, 2015. Also Etfdailynews.com published the news titled: “Aquinox Pharmaceuticals Inc (AQXP): How This Biotech Stock Trapped Investors” on August 17, 2015. Quotes.Wsj.com‘s news article titled: “News Aquinox Pharmaceuticals Inc.AQXP” with publication date: March 05, 2014 was also an interesting one.
AQXP Company Profile
Aquinox Pharmaceuticals, Inc., incorporated on May 25, 2007, is a clinical-stage pharmaceutical firm discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Firm operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Firm is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial investigating the ability of over 200 milligrams oral, once daily AQX-1125 to reduce pain and urinary symptoms in female patients with IC/BPS.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.